NCT02555358View on ClinicalTrials.gov

Three Drugs in Advanced Gastric Cancer Neoadjuvant Chemotherapy for Stage Ⅲ Clinical Study

PHASE2CompletedINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

November 30, 2014

Primary Completion Date

December 31, 2021

Study Completion Date

June 30, 2022

Conditions
Gastric Cancer
Interventions
DRUG

docetaxel,0xaliplatin,capecitabine

docetaxel 60mg/m2， ivgtt，2h，d1;capecitabine 1000mg/m2 po bid d1-14; oxaliplatin 130mg/m2， ivgtt，2h，d1;q21d

DRUG

oxaliplatin,capecitabine

oxaliplatin 130mg/m2， ivgtt，2h，d1;capecitabine 1000mg/m2 po bid d1-14;q21d

Trial Locations (1)

050011

Fourth Affiliated Hospital of Hebei Medical University, Shijiazhuang

All Listed Sponsors
collaborator

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

lead

Qun Zhao

OTHER

NCT02555358 - Three Drugs in Advanced Gastric Cancer Neoadjuvant Chemotherapy for Stage Ⅲ Clinical Study | Biotech Hunter | Biotech Hunter